Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells

Cancer Research

Volumn 65, Issue 3, 2005, Pages 1055-1062

  Ukon, Kei ^a   Tanimoto, Keiji ^a   Shimokuni, Tatsushi ^a   Noguchi, Takuya ^a   Hiyama, Keiko ^a   Tsujimoto, Hiroaki ^b   Fukushima, Masakazu ^b   Toge, Tetsuya ^a   Nishiyama, Masahiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BINDING SITE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENE CONTROL; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROMOTER REGION;

BINDING SITES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; IONOMYCIN; KIDNEY; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; STOMACH NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 13444257365     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Beck A, Etienne MC, Cheradame S, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994;30:1517-22.
2. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998;12:23-7.
3. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999;5:2672-3.
4. Fischel JL, Etienne MC, Spector T, et al. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1995;1:991-6.
5. DiPaolo A, Chu E. The role of thymidilate synthase as a molecular biomarker. Clin Cancer Res 2004;10:411-2.
6. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47:2203-6.
7. Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999;5:2006-11.
8. van Kuilenburg ABP, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.
9. Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002;3:75-82.
10. Collie-Duguid ESR, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10:217-23.
11. Noguchi T, Tanimoto K, Shimokuni T, et al. Aberrant methylation of dihydropyrimidine dehydrogenase gene (DPYD) promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004;10:7100-7.
12. Shestopal SA, Johnson MR, Diasio RB. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochim Biophys Acta 2000;1494:162-9.
13. Collie-Duguid ESR, Johnston SJ, Powrie RH, et al. Cloning and initial characterization of the human DPYD gene promoter. Biochim Biophys Res Commun 2000;271:28-35.
14. Tanimoto K, Yoshiga K, Eguchi H, et al. Hypoxia-inducible factor-1α polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003;24:1779-83.
15. Tanimoto K, Eguchi H, Yoshida T, et al. Regulation of estrogen receptor α gene mediated by promoter B responsible for its enhanced expression in human breast cancer. Nucleic Acids Res 1999;27:903-9.
16. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of hypoxia-inducible factor-1α by von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19:4298-309.
17. Raida M, Kliche KO, Schwabe W, et al. Orcadian variation of dihydropyrimidine dehydrogenase mRNA expression in leukocytes and serum Cortisol levels in patients with advanced gastrointestinal carcinomas compared to healthy controls. J Cancer Res Clin Oncol 2002;128:96-102.
18. Porsin B, Formento JL, Filipski E, et al. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur J Cancer 2003;39:822-8.
19. Yamashita K, Mikami Y, Ikeda M, et al. Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. Cancer Lett 2002;188:231-6.
20. Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999;5:2620-8.
21. Uchida K, Hayashi K, Kuramochi H, Takasaki K. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int J Oncol 2001;19:34-6.
22. Kashima N, Ueda M, Kanazawa J. Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells. Cancer Sci 2003;94:821-5.
23. Ueda M, Kitaura K, Kusada O, et al. Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleotide phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells. Jpn J Cancer Res 2000;91:1185-91.
24. Johnston S, Ridge SA, Cassidy J, McLeod HL. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 1999;5:2566-70.
25. Lee HW, Ahn DH, Crawley SC, et al. PMA upregulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-κB. J Biol Chem 2002;277:32624-31.
26. Chun YS, Lee KH, Choi E, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1α isoform: implication for tumor promotion. Cancer Res 2003;63:8700-7.
27. Liu Y, Ludes-Meyers J, Zhang Y, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002;21:7680-9.
28. Eferl R, Wanger EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev 2003;3:859-68.
29. Scott RE, Boone CW. Promotion of smooth surface tumorigenicity by phorbol myristate acetate in Balb/3T3 cells and Balb/3T3 T proadipocytes. J Natl Cancer Inst 1981;66:733-6.